![]() | This article needs more reliable medical references for verification or relies too heavily on primary sources. (August 2023) | ![]() |
![]() | |
Clinical data | |
---|---|
Trade names | Dostinex, others |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | First-pass effect seen; absolute bioavailability unknown |
Protein binding | Moderately bound (40–42%); concentration-independent |
Metabolism | Liver, predominately via hydrolysis of the acylurea bond or the urea moiety |
Elimination half-life | 63–69 hours (estimated) |
Excretion | Urine (22%), feces (60%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.155.380 |
Chemical and physical data | |
Formula | C26H37N5O2 |
Molar mass | 451.615 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications.[1] It is taken by mouth.
Cabergoline is an ergot derivative and a potent dopamine D2 receptor agonist.[2]
Cabergoline was patented in 1980 and approved for medical use in 1993.[3] It is on the World Health Organization's List of Essential Medicines.[4]